Microsatellite instability (MSI) characterized by alterations at simple repetitive genomic sequences is a distinct mechanism in tumorogenesis. Central nervous system (CNS) tumors have been reported to exhibit MSI, indicator of defective mismatch repair system with controversies. The present study was undertaken to examine sixteen primary brain and two spinal tumors for MSI at six mono: BAT -26, BAT -40, BAX, TGF~RII, IGFliR and hMSH3 and four dinucleotide loci: D2S123, D9S1851, D9S283 and D18S58. Polymerase chain reaction (PCR) was done to amplify tumour and blood DNA, analyzed on 8% denaturing Polyacrylamide gel followed by autoradiography. Out of 18 CNS tumors examined, 39% exhibited MSI at BAT -26, BAT -40, D9S1851, D9S283 and D18S58 in tumoral DNA. However, no alteration was observed at BAX, TGFI~RII, IGFIIR, hMSH3 and D2S123 loci. Low incidence of MS1 -high hypothesizes role of MSI in evolution of CNS tumors but not in cancer initiation or progression.
INTRODUCTION
Genetic instability is manifested as an altered DNA repair property which is one of the major driving forces in the generation of cells with increased invasive and metastatic potential indicated by alteration at microsatellite sequences.
Microsatellites are the short repetitive nucleotide sequences dispersed through out the genome. The tandem nature of elemental units within simple repeats undergoes slipped strand mispairing and therefore, results in insertion and deletion mutagenesis (1) . Microsatellite instability (MSI) is defined as a change in the sequences at repetitive
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motifs, which can be either contraction or expansion. This altered pattern can be observed as a shift in electophoretic mobility of microsatellite alleles (2) . Since MSI is due to defect in replication or mismatch repair system, it is also called as replication error positive phenotype (RER +ve). MSI can be at one locus or at multiple loci according to which it has been classified as MSI -L (low) if it is at <30% of the loci studied and MSI -H (high) if it is at _> 30% of the loci examined (2, 3) .
Microsatellite instability was first reported in 80 -85% in Hereditary non polyposis colorectal cancer (HNPCC) associated with inactivating mutations in human mismatch repair (MMR) genes -hMSH2, hMLH1, hPMS1, hPMS2 and hMSH6. This defect is also seen in 10 -15% of sporadic colorectal cancers and in many other cancers like endometrial, skin, pancreatic, lung, stomach, renal, esophageal, ovary, cervix, bladder, breast, testis, prostate, liver and brain with lot of variations (4).
Central nervous system (CNS) tumors exhibit wide range of both benign and malignant tumors that are clinically distinct and their different behavior could be attributed to genetic differences (5, 6 (7, 8) . Recently a study from Hungary reports very high prevalence of microsatellite instability that is 54.5% and 45.5% in primary and recurrent gliomas but no alteration was found in hMLH1 and hMSH2 genes (9) . The present study has been initiated to evaluate the pattern of microsatellite alterations with the panel of six mono -and four dinucleotide markers situated on different chromosomes in 16 brain and 2 spinal tumors to look for the presence of genetic changes caused by defects in mismatch repair genes.
MATERIAL AND METHODS

Patient selection
Patients were enrolled in the Neurosurgery Department of our institute. The diagnosis was based on clinical and laboratory investigations according to standard Proforma. Sixteen of total eighteen cases presenting with intracranial mass lesions, irrespective of histological nature of masses were operated on account of their neurological indications while remaining 2 cases were spinal tumors which were operated because of their progressive neurological deficit. All masses were biopsied and tumor substance was subjected for MSI studies using blood as control of the same individual. Histological reports were obtained simultaneously before discharging the patients. Histopathology of the tumors/ masses turned out All the cases were sporadic and had no familial history for CNS tumor. The age of patients ranged from 7 years to 63 years. The histopathological features of central nervous system tumors are described (see Table 1 ).
DNA extraction from blood and tissue specimen
Tumor tissue biopsy of histologically confirmed tumors and peripheral blood collected in EDTA which would serve as control of the same patient was taken. DNA was isolated from tissue as well as blood using phenol-chloroform extraction method (10) .
MSl Analysis
Six mono -and four dinucleotide microsatellite markers were examined for MSI in CNS tumors ( Table 2 ). The primer sequences for each microsatellite marker were searched from human genomic data base (10 The tumor was called unstable if its PCR product had altered band pattern when compared to alleles in corresponding matched blood DNA (11) .
RESULTS
Microsatellite Alterations
Ten microsatellite markers were examined by PCR in tumor tissue and blood separately of the corresponding matched individuals in 16 brain and 2 spinal tumors. Out of the total central nervous system tumors/ masses analyzed, 39% (7/18) of them were found to have genetic alterations. Two of the six mononucleotide and three of the four- (12), activation of proto -oncogenes N -MYC in neuroblastomas (13), c -MYB in glioblastomas. EGFR in gliomas, c -MYC in medulloblastomas (14) and rare HRAS1 allele in glial neoplasms (15) . Recently another type of genetic abnormality resulting from defect in mismatch repair genes has been reported in many tumors of brain. Vadous studies in different types of brain tumors came up in the last ten years but they showed conflicting results (16) . The abnormal function of mismatch repair genes revealed by presence of widespread MSI acts as a novel mechanism in tumor development. We undertook the present study to find out the role of MSI in Indian patients with CNS tumors. We observed 39% of total MS1 in 16 brain and 2 spinal tumors of varied histological types. Cases presenting with epidermoid, plasmacytoma, hemangiopericytoma, grade 111 glioma and pituitary macroadenoma showed 5.5% of MSI but no change was observed in glioblastoma. However, one of the previous studies showed low MSI in glioblastomas but not in astrocytomas with different panel of markers (17) . One of our cases was of multiple tuberculomas of brain while another child with acute lymphoblastic leukemia who once developed leukemic infiltration of brain along with fungal granuloma formation also exhibited MSI. We did not observe any MSI in meningiomas, Schwannoma and paraganglioma which is not in concordance with an earlier study demonstrating 2.4% MSI in meningiomas, 3% in astrocytic tumor, 17.4% in oligodendro-gliomas and 3.2% in pituitary adenoma using different microsatellite markers (18) .
In present study, contraction at BAT -26 in multiple intracranial tuberculoma; expansion at BAT -26 and BAT 40 in plasmacytoma, hemangiopericytoma, grade III glioma and pituitary macroadenoma; biallelic alteration at D9S1851 in epidermoid and LOH at D9S283 and D18S58 in aspergilloma with leukemic infiltration, epidermoid and pituitary macroadenoma were observed. No change was noticed in glioblastomas in our study with present set of markers and it differs from the previous finding which demonstrated genetic defect as LOH in 10% of glioblastomas (19) .
Out of the ten loci studied, the loci present on 13 hydroxy steroid dehydrogenase gene, hMSH2 (2p) and 9q13-q22 showed allelic shifts and imbalance, which may be indicative of defective, mismatch repair system. LOH at D9S283 and D18S58 may hypothesize the presence of putative tumor suppressor gene at chromosomes 9 and 18 near to these loci. Other four mononucleotide repetitive motifs TGFI3RII, IGFIIR, BAX and hMSH3 present in exonic regions did not exhibit any change in CNS tumors while an earlier study demonstrated the presence of MSI at these loci in gliomas (20) . D2S123 situated in intronic region of 2p16 was found to be microsatellite stable (MSS) for all CNS tumors. Therefore, absence of instability rules out the possibility of any genetic defect at TGFI3RII, IGFIIR, BAX, hMSH3 and D2S123 loci.
Following the criterion of MSI classification into MSI L and MSI -H we observed MSI -H in only 28.6% of unstable CNS tumors as, compared to MSI -L which was found in 71.4% of unstable cases. Low incidence of MSI -H suggests that CNS tumors differ from HNPCC where MSI -H is intimately associated with tumor initiation as well as progression. Therefore, it can be hypothesized that MSI only helps in the evolution of tumor in central nervous system but not in cancer initiation and progression that is later on overtaken by other genetic pathways.
We observed higher incidence of MSI (50%) inpatients above 50 years of age as compared to tumors in younger age group but more studies would be required to substantiate this observation because our group is too small to make a conclusion.
In conclusion, our study shows that 39% of histologically varied CNS tumors harbor microsatellite alterations at low level but instability at multiple loci is infrequent. These results extend the observation that pathway for tumorogenesis in human central nervous system is different from HNPCC and thus low incidence of MSI -H hypothesizes that MSI in CNS tumors may result in tumor evolution but not in its initiation and progression. The presence of tumor suppressor gene at chromosomes 9 and 18 involving in tumorigenesis may be hypothesized. These studies open new avenues to focus MSI analysis in large number of central nervous system tumors with expanded panel of microsatellite markers for better understanding the mechanism of their pathogenesis.
